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Abstract
Background: In endothelial cells, activation of the AMP-activated protein kinase (AMPK) has been linked with anti-
inflammatory actions but the events downstream of kinase activation are not well understood. Here, we addressed the
effects of AMPK activation/deletion on the activation of NFkB and determined whether the AMPK could contribute to the
anti-inflammatory actions of nitric oxide (NO).
Methodology/Principal Findings: Overexpression of a dominant negative AMPKa2 mutant in tumor necrosis factor-a-
stimulated human endothelial cells resulted in increased NFkB activity, E-selectin expression and monocyte adhesion. In
endothelial cells from AMPKa2
-/- mice the interleukin (IL)-1b induced expression of E-selectin was significantly increased.
DETA-NO activated the AMPK and attenuated NFkB activation/E-selectin expression, effects not observed in human
endothelial cells in the presence of the dominant negative AMPK, or in endothelial cells from AMPKa2
-/- mice.
Mechanistically, overexpression of constitutively active AMPK decreased the phosphorylation of IkB and p65, indicating a
link between AMPK and the IkB kinase (IKK). Indeed, IKK (more specifically residues Ser177 and Ser181) was found to be a
direct substrate of AMPKa2 in vitro. The hyper-phosphorylation of the IKK, which is known to result in its inhibition, was also
apparent in endothelial cells from AMPKa2
+/+ versus AMPKa2
-/- mice.
Conclusions: These results demonstrate that the IKK is a direct substrate of AMPKa2 and that its phosphorylation on Ser177
and Ser181 results in the inhibition of the kinase and decreased NFkB activation. Moreover, as NO potently activates AMPK
in endothelial cells, a portion of the anti-inflammatory effects of NO are mediated by AMPK.
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Introduction
The AMP-activated protein kinase (AMPK) is a member of the
Snf1/AMPK family of serine/threonine protein kinases and is an
evolutionarily conserved sensor of the cellular energy status.
Although the AMPK pathway is traditionally thought of as an
intracellular fuel gauge and regulator of metabolism, recent
evidence indicates that it may also be important for the
maintenance of endothelial function and to redress the disturbed
redox balance associated with vascular disease. Certainly, the
AMPK can influence a number of signaling cascades that would
be expected to result in anti-atherosclerotic effects, such as
attenuated free radical generation and the activation of angiogenic
factors (for review see [1]).
Although the link between cellular metabolism and AMPK
activation has been repeatedly demonstrated in tissues such as
skeletal and cardiac muscle [2], the precise role played by the
AMPK in endothelial cell remains incompletely understood.
Indeed, while there are some situations in which activation of
the AMPK is reported to depend on an increase in the ADP/ATP
ratio e.g. following cell stimulation with rosiglitazone [3], the
activation of AMPK by Ca
2+-elevating agonists such as bradykinin
[4,5] and thrombin [6] has been attributed to the activity of an
upstream activating kinase rather than to changes in AMP levels.
There are two different isoforms of the catalytic a AMPK subunit
(a1 and a2) that are differentially expressed in different tissues. For
example, while the a1 isoform predominates in adipose tissue,
skeletal muscle and cardiomyocytes express higher amounts of the
AMPKa2 [7]. Interestingly, endothelial cells express both a
subunits and different groups report the predominance of different
isoforms, a finding that may explain the inconsistent dependence
on changes in ADP/ATP for stimulation.
We reported previously that the AMPK can be activated by
fluid shear stress as well as by NO in endothelial cells, and that it
can affect the expression of endothelial cell proteins including, the
hydroxy-methylglutaryl coenzyme A reductase, cytochrome P450
2C8, and angiopoietin 2 [8–11]. Also the overexpression of
dominant negative AMPKa2 in endothelial cells increases basal
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sion [10]. While the latter findings imply the involvement of the
transcription factor nuclear factor kB (NFkB) and there are reports
of an attenuated NFkB activation following AMPK activation in
different cell types [12–15], the molecular mechanisms involved
are not clear. Therefore, the aim of the present study was to
address the link between AMPK activation and NFkB inhibition
as well as to determine whether or not the activation of the AMPK
could at least partially account for the effects of NO on NFkB
activity and thus adhesion molecule expression.
Results
Effect of NO on the activation of AMPK and NFkB
Treatment of primary cultures of human endothelial cells
with the NO donor DETA-NO (100 mmol/L) which has a tK of
16 hours, elicited the time-dependent phosphorylation of the
AMPK on Thr172 (Figure 1A). The phosphorylation of AMPK
by exogenous NO was independent of the donor used as a
substance with a markedly faster NO releasing kinetic i.e., DEA-
NO, tK 2m i n u t e s ,r e s u l t e di nt h em o re rapid activation of the
AMPK i.e., within 2 minutes (Figu r eS 1 A ) .T h ee f f e c t sw e r ea l s o
concentration-dependent as indicated using a third NO donor
with a more delayed NO release (DPTA NO, tK 5h o u r s ;F i g u r e
S1B). TNF-a (1 and 10 ng/ml, 30 min) elicited a marked and
concentration-dependent increase in NFkB activity (EMSA;
Figure 1B), that was attenuated by endothelial cell pre-
treatment with DETA-NO (Figure 1B). TNF-a had however
no acute effect on the activation of the AMPK in the absence of
NO (Figure 1C).
Effect of constitutively active and dominant negative
AMPK mutant on NFkB activation
To determine the involvement of the AMPK in the prevention
of NFkB activation, we assessed the effects of constitutively active
and dominant negative AMPKa2 mutants on the TNF-a-induced
activation of NFkB. While TNF-a enhanced the activity of NFkB
in cells infected with a control virus, this response was blunted in
cells overexpressing the constitutively active AMPK (Figure 2A)
and potentiated in cells expressing the dominant negative AMPK
mutant (Figure 2B). To estimate the influence of the AMPK in the
NO-mediated inhibition of TNF-a-induced NFkB activation, cells
overexpressing either the control virus or the dominant negative
AMPK mutant were exposed to TNF-a in the absence and
presence of DETA-NO. As before, pre-treatment with the NO
donor attenuated the activation of NFkB (Figure 2C). The effect of
NO was however blunted in cells overexpressing the dominant
negative AMPK mutant.
Effect of AMPK deletion on E-selectin and VCAM-1
expression in murine endothelial cells
Theoretically a dominant negative AMPKa2 mutant could
affect the activity of the AMPKa1 by, for example, sequestering
AMPKb and c subunits from the endogenous a1 subunit. To
ensure that the effects observed could indeed be attributed to the
AMPKa2, we performed additional experiments in endothelial
cells from AMPKa2
-/- mice or their wild-type littermates
(AMPKa2
+/+).
First, to determine whether or not the loss of one AMPKa
subunit could result in the compensatory up regulation of the other
we assessed AMPKa1 expression in aortae from a2
+/+ and a2
-/-
mice as well as AMPKa2 expression in a1
+/+ and a1
-/- mice. We
found that the deletion of the AMPKa2 did not affect a1
expression while the a2 subunit was upregulated in tissue from
AMPKa1
-/- mice (Figure S2).
To determine the effect of AMPK deletion on the response to
inflammatory mediators, murine microvascular endothelial cells
from AMPKa2
+/+ or AMPKa2
-/- mice were exposed to IL-1b
(10 ng/mL, 6 hours) or to LPS (10 ng/mL, 6 hours) in the
absence and presence of DETA-NO and the surface expression of
E-selectin was assessed. The basal expression of E-selectin was
slightly (but not significantly) enhanced in cells isolated from the
AMPKa2
-/- compared to the AMPKa2
+/+ animals. While the
basal expression of the adhesion molecule was attenuated by NO,
levels remained slightly elevated in the AMPKa2
-/- cells. Cell
stimulation with IL-1b (Figure 3A) or LPS (Figure 3B) increased
the expression of E-selectin with significantly higher expression
levels being detected in AMPKa2
-/- cells. TNF-a failed to result in
the activation of NFkB in either AMPKa2
+/+ or AMPKa2
-/- cells
studied. Pre-treatment of endothelial cells with the NO donor
attenuated adhesion molecule expression but again expression was
higher (2.561.0-fold for IL-1b and 1.760.4-fold for LPS) in the
cells from AMPKa2
-/- mice than in cells from their wild-type
littermates.
Figure 1. Effect of DETA-NO on AMPK and NFkB activation.
Human endothelial cells were treated with either solvent (PBS) or DETA-
NO (100 mmol/L) for (A) the times indicated or (C) 16 hours before
stimulation with TNF-a (1 or 10 ng/mL) for 30 minutes. (A&C) Western
blots showing the consequences of DETA-NO on the phosphorylation
of the AMPK (p-Thr172) in the absence (A) and presence (C) of TNF-a.
(B) The TNF-a-induced activation of NFkB in the absence and presence
of DETA-NO was assessed by EMSA. The bar graph summarizes the
results from 4–8 independent experiments; *P,0.05, **P,0.01 versus
the appropriate Sol-treated group. The Western blots are representative
of 2 additional experiments.
doi:10.1371/journal.pone.0020848.g001
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AMPK mutants on cell adhesion
Next, we studied the consequences of AMPK mutant overex-
pression on the adhesion of mononuclear cells to endothelial cells.
Consistent with the results obtained using the AMPKa2
-/- murine
endothelial cells, significantly more mononuclear cells attached
firmly to human endothelial cells overexpressing the dominant
negative AMPKa2 mutant than those expressing the constitutively
activeAMPKortreated with the control virus. Cellstimulationwith
TNF-a (1 ng/mL, 6 hours) resulted in a significant increase in
mononuclear cell attachment (Figure 4) that was potentiated in cells
expressing the dominant negative, but attenuated in cells expressing
the constitutively active AMPK mutants.
Consequences of AMPK activation/inactivation on IkB
The activation of NFkB mainly occurs via the phosphorylation
and degradation of inhibitory molecules, including IkB. Interest-
ingly, the activation of the AMPK was associated with the
increased expression of IkB protein, a phenomenon that was
evident on comparing pulmonary endothelial cells from
AMPKa2
+/+ and AMPKa2
-/- mice (Figure 5A) or COS-7 cells
overexpressing the constitutively active or dominant negative
AMPKa2 mutants (Figure 5B). Both these findings support the
above evidence indicating that activation of the AMPK results in
NFkB inhibition. No difference in IkB expression was detected
between AMPKa1
+/+ and AMPKa1
-/- endothelial cells (data not
shown).
Figure 2. Effect of constitutively active and dominant negative
AMPK mutants on NFkB activation. Human endothelial cells
infected with either control (CTL) virus or adenoviral constructs
encoding (A) constitutively active (CA) or (B&C) dominant negative
(DN) AMPK mutants. After 48 hours cells were treated with TNF-a (1 or
10 ng/mL) for 30 minutes and NFkB activity determined by EMSA. In
some experiments (C), cells were pre-treated with DETA-NO (100 mmol/
L) prior to TNF-a stimulation. The bar graph summarizes the results of
data obtained in 4 (A), 6 (B) or 5 (C) independent experiments; *P,0.05,
**P,0.01, ***P,0.001 versus the appropriate Sol group and
1P,0.05,
11P,0.01,
111P,0.001 versus cells treated with CTL virus.
doi:10.1371/journal.pone.0020848.g002
Figure 3. Effect of AMPK deletion on adhesion molecule
expression and IkB stability. Lung endothelial cells from AMPKa2
-/-
mice or their wild-type (+/+) littermates were treated with either IL-1b
(10 ng/mL) or LPS (10 ng/mL) in the absence (or presence of DETA-NO
(100 mmol/L, 24 hours) for 6 hours. Surface protein expression of (A)E -
selectin and (B) VCAM-1 were determined by FACS analysis. The bar
graphs summarize the results of data obtained in 4 independent
experiments; ***P,0.001 versus Sol-treated cells, 11P,0.01,
111P,0.001 and {{P,0.01.
doi:10.1371/journal.pone.0020848.g003
AMPK Phosphorylates and Inhibits IkB Kinase
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20848COS-7 cells expressing constitutively active or dominant
negative AMPKa2 were used to determine the consequences of
AMPK activation and inhibition on the IkB kinase (IKK)-
mediated phosphorylation of IkB independent of potential
interference by endogenously generated NO. Neither of the
AMPKa2 mutants studied affected the basal IkB phosphorylation.
However, following stimulation with TNF-a (10 ng/mL), IkB
phosphorylation was enhanced in cells expressing the dominant
negative mutant (Figure 5C). The lack of effect of the constitutively
active AMPK mutant in these cells can most probably be
attributed to the high expression level and activity of the
endogenous AMPKa isoforms in this cell line.
The TNF-a-activated IKK complex also phosphorylates p65 on
Ser536, a step thought to be required for enhanced p65
transactivation potential and the optimal induction of NFkB
target genes [16]. The AMPK also seems to play a role in this
pathway as we observed that the expression of the constitutively
active AMPK led to a decrease in the TNF-a-stimulated
phosphorylation of p65 (Figure S3). Similar results were obtained
using human endothelial over expressing the AMPKa2 but not the
AMPKa1 subunit (data not shown).
Consequences of AMPK activation/inactivation on IKK
Given that AMPK activation attenuated the phosphorylation of
IkB as well as p65 we proposed that the AMPK is able to attenuate
NFkB activation by phosphorylating and inhibiting the IKK. In in
vitro kinase assays using the purified AMPKa2 (together with b1
and c1) we identified IKKb as an AMPK substrate (Figure 6A).
To determine the site(s) in IKKb phosphorylated by AMPK we
replaced its major phosphorylation sites i.e. Ser177 and Ser181
with alanine by site-directed mutagenesis, and overexpressed these
mutants in COS-7 cells. The wild-type and mutant IKKb were
then immunoprecipitated and incubated with AMPKa2. We
found that the mutation of IKKb on Ser177 and Ser181 resulted
in a lower level of phosphorylation than the wild-type enzyme.
Moreover, phosphorylation was barely detectable in the S177A/
S181A double mutant. When IKKb was replaced with GFP, no
phosphorylation was observed in the presence of AMPKa2
(Figure 6B). Also in COS-7 cells overexpressing a constitutively
active AMPKa2 mutant the phosphorylation of IKK (the antibody
used recognizes phospho Ser177 and 181) was increased
compared to that detected in cells treated with a control virus
(Figure 6C). A similar, approximately 2-fold increase in pIKK
levels was observed in murine endothelial cells stimulated with IL-
1b (30 ng/mL, Figure 6D) in that the phosphorylation of IKK was
consistently greater in cells from AMPKa2
+/+ versus a2
-/- mice.
Signals from solvent-treated cells were too low to quantify. There
was no difference in the IL-1b -induced phosphorylation in
AMPKa1
+/+ and AMPKa1
-/- mice (Figure S4).
To assess IKKb activity we next determined the phosphoryla-
tion of GST-IkBa in the presence of wild-type IKKb and either
AMPKa1o ra2. We found that the phosphorylation of IkBa was
reduced in the presence of AMPKa2 but not AMPKa1
(Figure 6E).
Figure 4. Effect of constitutively active and dominant negative
AMPK mutants on monocyte adhesion. Human endothelial cells
were infected with either a control (CTL) virus or adenoviral constructs
encoding a constitutive active or dominant negative (DN) AMPKa2
mutants. After 48 hours in culture, cells were treated with either solvent
or TNF-a (10 ng/ml, 6 hours) before the addition of freshly isolated
PBMCs (4610
5 per well) for 10 minutes. The bar graph summarizes data
obtained in 4 independent experiments, each performed in quadrupli-
cate; *P,0.05, **P,0.01 solvent treated cells expressing CTL virus and
1P,0.05, 11P,0.01 versus cells expressing the DN mutant.
doi:10.1371/journal.pone.0020848.g004
Figure 5. Role of AMPKa2 in regulating the expression and
phosphorylation of IkB. Expression of IkBi n( A) pulmonary
endothelial cells from AMPKa2
+/+ and AMPKa2
-/- mice, and (B)i n
COS-7 cells expressing either constitutively active (CA) or dominant
negative (DN) AMPKa2. (C)I kB phosphorylation in CA- or DN-AMPKa2
expressing COS-7 cells and stimulated with solvent (Sol) or TNF-a
(10 ng/mL). Data are expressed relative to values obtained in control
virus-infected cells. The bar graphs summarize the results of 4 to 5
independent experiments; *P,0.05 versus CA or
+/+.
doi:10.1371/journal.pone.0020848.g005
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The results of the present investigation indicate that the
AMPKa2 subunit plays an important role in regulating inflam-
matory responses, adhesion molecule expression (E-selectin and
VCAM-1) and monocyte adherence to endothelial cells. These
effects could be related, at least partly to the AMPK-mediated
phosphorylation of IKK and subsequent inhibition of IkB and p65
phosphorylation as well as DNA binding (see Figure 7). Moreover,
three different NO donors were able to activate the AMPK and
the NO-mediated inhibition of NFkB activation was attenuated by
a dominant negative AMPK in human endothelial cells as well as
in endothelial cells from AMPKa2
-/- mice. Thus, it appears that
the NO-mediated inhibition of NFkB activity is, at least partially,
dependent on the activation of the AMPKa2 subunit.
The possibility that the AMPK can regulate the DNA binding
activity of NFkB was initially indicated by the fact that
overexpression of a dominant negative AMPK increased, while a
constitutively active AMPK decreased the TNF-a-induced ex-
pression of E-selectin [10]. There have since been reports linking
AMPK with NFkB in endothelial cells, but the overall outcome of
kinase activation is controversial as both NFkB inhibition [12,17–
19] and activation [20–23] have been reported. Whether or not
this discrepancy can be attributed to the parallel activation/
inactivation of associated regulatory mechanisms and signal
Figure 6. Identification of IKK as an AMPKa2 substrate. (A) Autoradiograph showing the in vitro phosphorylation (
32P) of purified IKKb by
AMPKa2. Similar results were obtained in 2 additional experiments. (B) Effect of the substitution of Ser177 and Ser181 with alanine on the AMPKa2-
dependent phosphorylation of IKKb. GFP was used instead of IKKb as a negative control. (C) Phosphorylation of IKK in solvent (Sol)- or TNF-a-
stimulated COS-7 cells 48 hours after infection with either CTL or constitutively active (CA) AMPKa2 adenoviruses. Similar results were obtained in 2
additional experiments. (D) Phosphorylation of IKK in solvent (Sol)- or IL-1b -stimulated endothelial cells from AMPKa2
+/+ and a2
-/- mice. (E)
Autoradiograph of phosphorylated GST-IkB after IKK activity assay in the presence of protein A/G (CTL) or immunoprecipitated AMPKa2 or AMPKa1
subunits. Similar results were obtained in three different experiments. The bar graphs summarize the data from 4 (B and E) to 8 (D) independent
experiments; *P,0.05, **P,0.01 ***P,0.001 versus WT or
+/+.
doi:10.1371/journal.pone.0020848.g006
Figure 7. Scheme of the mechanism proposed. NO Initiates the
activation of the AMPKa2 in endothelial cells which in turn
phosphorylates and activates the b-subunit of the IKK. The latter also
induces a higher rate of IKK auto-inactivation and thus attenuates the
activation of NFkB and the expression of inflammatory genes.
doi:10.1371/journal.pone.0020848.g007
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consideration is that much of the published data was generated
using the AMPK activator, 5-aminoimidazole-4-caboxymide-1-b-
D-ribofuranoside (AICAR), which can elicit AMPK-independent
effects [24], and substances such as compound C and iodotu-
bercidin which are by no means specific inhibitors of the AMPK.
Therefore, one focus of the current investigation was to make use
of the available constitutively active and dominant negative
AMPK mutants and endothelial cells from AMPKa2
+/+ and
AMPKa2
-/- mice to determine which of the catalytic subunits was
most likely to affect transcription factor activity. The results
obtained using murine lung endothelial cells indicate that the
AMPKa2 plays a prominent role in modulating NFkB phosphor-
ylation in endothelial cells.
Which point in the NFkB activation cascade could be affected
by AMPK? NFkB is a dimer consisting of the transcription factors
p65 (RelA) or p50, and under resting conditions it is associated
with its inhibitory protein IkB which retains the complex in the
cytosol. The activation of NFkB mainly occurs via the phosphor-
ylation of IkB, which results in its degradation - leaving the NFkB
dimer free to translocate into the nucleus and stimulate
transcription [16]. Using dominant negative and constitutively
active AMPK mutants we found that the phosphorylation of IkB
(residue Ser32 or Ser36) was increased when the AMPK was
inhibited but decreased when AMPK activity was increased. We
also observed the attenuated basal expression of IkB in the
AMPKa2
-/- versus AMPKa2
+/+ endothelial cells. As the expres-
sion of IkB is known to be regulated by the activity of NFkB [25],
these data further highlight the importance of the AMPKa2
subunit in the regulation of transcription factor activity.
The serine phosphorylation of IkB is mediated by a large multi-
unit complex containing two catalytic subunits (IKKa and IKKb)
as well as the regulatory subunit IKKc or NEMO, which has no
kinase domain. The p65 subunit is also a IKK substrate and p65
phosphorylation on Ser536 is thought to be required for enhanced
p65 transactivation potential and the optimal induction of NFkB
target genes [16]. Given that we observed that both AMPK
activation and a constitutively active AMPK mutant decreased the
phosphorylation of IkB and p65, it seemed logical to conclude that
the AMPK is able to modulate the activity of the IKK complex.
To date there has only been circumstantial evidence to suggest a
role of the AMPK in the modulation of IKK activity. For example,
AICAR has been reported to be without effect on IKK in rat
skeletal muscle cells [26] but to attenuate IkB phosphorylation in
IL-18-stimulated cardiac microvascular endothelial cells [27].
Moreover, the overexpression of a dominant-negative AMPK in
TNF-a–stimulated mouse macrophages resulted in the accelerated
and exaggerated degradation of IkB [28]. Similarly, during the
preparation of this manuscript the loss of AMPK activity was
reported to result in increased IkBa degradation in cultured
endothelial cells [23], a finding we have confirmed in native
endothelial cells. The results of the present study clearly indicate
that the AMPK can directly phosphorylate and attenuate the
activity of the IKK in native and cultured endothelial cells. In in vitro
assays we identified IKKb as an AMPK substrate and were able to
detect the elevated phosphorylation of IKK in intact AMPK-
overexpressing cells. The phosphorylation of IKKb on Ser 177
and/or 181 causes the rapid phosphorylation of a C-terminal serine
cluster which in turn elicits the auto-inhibition of kinase activity and
is thought to be an effective means of limiting the duration of IKK
activation [29]. Our data suggest that the AMPKa2 is able to
phosphorylate both of these serine residues as mutation of a single
site reduced phosphorylation which was only barely detectable in a
double S177A/S181A mutant. That the AMPK-mediated phos-
phorylation of the IKK most likely results in NFkB inhibition was
demonstrated by the fact that the IKK-dependent phosphorylation
of a IkB-GST construct was markedly attenuated in the presence of
the AMPKa2 but not the AMPKa1 subunit. Moreover, the
expression ofIkB was significantly higherinhuman endothelial cells
overexpressing the constitutively active AMPKa2 and in
AMPKa2
+/+ versus AMPKa2
-/- mouse endothelial cells.
The AMPK has been implicated in the phosphorylation and
activation of the endothelial NO synthase (eNOS), at least in vitro,
and thus one further mechanism by which the AMPK could affect
NFkB would be by modulating basal NO output (reviewed in [1]);
which is known to decrease NFkB activity [30]. However, using
COS-7 cells which do not express endogenous eNOS, we found
that AMPK activation and the constitutively active AMPK were
sufficient to attenuate the TNF-a-induced phosphorylation of IkB
and p65. Thus in our hands, the AMPK-dependent inhibition of
NFkB was not dependent on NO production. In fact, we were able
to confirm that NO donors are effective activators of the AMPK a
finding that fits well with previous reports in endothelial cells that
AMPK activation is markedly attenuated in the presence of a
NOS inhibitor or in cells from eNOS
-/- mice [5,9]. How NO
activates the AMPK remains to be elucidated but may well be
related to the activation of the Ca
2+/calmodulin-dependent
protein kinase kinase b, a well known AMPK kinase [5].
Taken together, the results of the present investigation indicate
that the activation of the AMPK in endothelial cells can limit
inflammatory responses via the phosphorylation and inhibition of
IKK activity. Moreover, as the AMPK could be activated by NO,
the AMPK dependent inhibition of IKK activity may contribute
to the anti-inflammatory and anti-atherosclerotic actions of the
endothelium-derived autacoid.
Materials and Methods
Materials
Antibodies for Western blotting directed against phospho-
Thr172 AMPK and total AMPK, phospho-Ser536 NFkB,
phospho-Ser32/36 IkB and phospho Ser 177/181 IkB kinase
(IKK) were purchased from New England Biolabs (Frankfurt,
Germany). Antibodies recognizing IkB, NFkB or IKK from Santa
Cruz Biotechnology (Heidelberg, Germany). Horseradish perox-
idase conjugated secondary antibodies were from Calbiochem
(Merck, Darmstadt, Germany) and the fluorescent antibodies
recognizing E-selectin and VCAM-1 used for FACS analyses were
from BD Biosciences (Pharmigen, Germany). TNF-a and
interleukin (IL)-1b, were from PeproTech (Cell Concept, Um-
kirch, Germany), and DETA-NONOate (DETA-NO), DEA-
NONOate and DPTA-NONOate were from Alexis (Lo ¨rrach,
Germany). The antibody against b-actin and other chemicals were
obtained from Sigma (Munich, Germany).
Cell culture
Human umbilical vein endothelial cells were isolated and
cultured as described [31]. The use of human material in this study
conforms to the principles outlined in the Declaration of Helsinki
[32] and was confirmed in written form by the members of the
Ethic-Commission of the Medical Faculty of the Goethe-
University (Frankfurt am Main, Germany) and the donors gave
verbal consent. Murine lung endothelial cells were isolated and
cultured as described [8], from AMPKa1
-/- or AMPKa2
-/- mice
or the respective littermate wild-type animals [33,34] (kindly
provided by Benoit Viollet, Paris via the European Mouse Mutant
Archive, Munich, Germany). The investigation conforms with the
Guide for the Care and Use of Laboratory Animals published by
AMPK Phosphorylates and Inhibits IkB Kinase
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University Animal Care Committee and the Federal Authority for
Animal Research at the Regierungspra ¨sidium Darmstadt (Hessen,
Germany) gave written approval to the study protocol (# F28/17).
For the isolation of the pulmonary endothelial cells, mice were
sacrificed using 4% isoflurane in air and subsequent exsanguina-
tion. COS-7 cells were purchased from the American Tissue
Culture Collection (LCG Standards, Wesel, Germany) and
cultured in Minimal Essential Medium (Invitrogen, Karlsruhe,
Germany) supplemented with 8% fetal calf serum, pyruvate, non
essential amino acids and gentamycin.
Adenoviral transduction of endothelial cells
Subconfluent endothelial cells (1
st passage) were infected with
adenoviruses (provided by Ken Walsh, Boston and Benoit Viollet,
Paris, France) to over-express constitutively active AMPKa2 [35],
or dominant-negative AMPKa2 [36], as described [10]. As the
viral backbones of the constitutive active and dominant negative
viruses were not identical, the observed effects were always
analyzed to the respective control virus.
Immunoblotting
Protein samples were heated with SDS-PAGE sample buffer
and separated by SDS-PAGE as described [8]. Proteins were
detected using their respective antibodies and enhanced chemilu-
minescence using a commercially available kit (Amersham,
Germany). To assess the phosphorylation of proteins, either equal
amounts of protein from each sample were loaded twice and one
membrane incubated with the phospho-specific antibody and the
other with an antibody recognizing total protein, or blots were re-
probed with the appropriate antibody.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear and cytosolic proteins were isolated, and binding to
c[
32P]-ATP (Hartmann Analytic, Braunschweig, Germany)-la-
beled double-stranded oligonucleotides containing the consensus
sequence of the binding site for transcription factor NFkB (5-AGT
TGA GGG GAC TTT CCC AGG C-3, Santa Cruz) was assessed
as described [37].
Flow cytometry
Following stimulation endothelial cells were harvested using
accutase (PAA laboratories, Coelbe, Germany) and washed twice
with PBS. After blocking (1% BSA, 15 minutes, 4uC) cells were
incubated with the specific conjugated antibodies (30 minutes, 4uC),
washed twice with PBS and fixed in 1% paraformaldehyde.
Antibody binding was analyzed using a flow cytometer (FACSCa-
libur, BD) by counting 20,000 cells per sample. The values are
presented following subtraction of the isotype-matched, control IgG.
Adhesion assay
Peripheral blood mononuclear cells were freshly isolated from
blood obtained from healthy volunteers using a BiocollH (1.077 g/
ml) gradient (Biochrom AG, Berlin, Germany) according to the
manufacturer’s protocol. Confluent cultures of human endothelial
cells were stimulated with TNF-a for 6 hours, and were washed
with culture medium before freshly isolated mononuclear cells
(400,000 per 12 well) were added. After 10 minutes of incubation
the non-adherent cells were removed the number of firmly
adherent cells was quantified.
IKKb kinase assays
The phosphorylation of IKKb by AMPKa2 and the activity of
IKK b were assessed in in vitro kinase assays. Ser177 and Ser181
in a flag-tagged IKK plasmid [38] (Addgene, Cambridge, MA)
were mutated to alanine by site-directed mutagenesis (Quick
exchange Kit, Agilent, Bo ¨blingen, Germany) using specific
oligonucleotides (Biospring, Frankfurt, Germany). COS-7 cells
were transfected with a plasmid encoding either the wild-type flag-
tagged IKKb or one of the S177A, S181A or S177A/181A
mutants, which were then immunoprecipitated using a Flag
antibody (Invitrogen, Karlsruhe, Germany). The AMPKa2
subunit was also immunoprecipitated from COS-7 cells and the
in vitro kinase reaction performed as described [9]. In some
experiments the activity of the IKKb was detected by monitoring
the phosphorylation of a GST-IkB fusion protein (kindly provided
by Fumiyo Ikeda, Frankfurt).
Statistical analysis
Values are expressed as the mean 6 SEM and statistical
evaluation was performed using Student’s t test for unpaired data
and one-way ANOVA or ANOVA for repeated measures followed
by followed by a Bonferroni t test where appropriate. Values of
P,0.05 were considered statistically significant.
Supporting Information
Figure S1 Effect of NO donors on the phosphorylation
of AMPK. (A) Human endothelial cells (passage 2) were treated
with either solvent (Sol) or DEA-NO (100 mmol/L, tK 16
minutes) for up to 30 minutes. Identical results were obtained in
two additional experiments. (B) Human endothelial cells were
treated with different concentrations of the NO donor DPTA
NONOate (tK 5 hours) and the phosphorylation of the AMPK
was detected by Western blotting. The graph summarizes the data
obtained in 3 independent experiments; **P,0.01 versus the
appropriate Sol-treated group.
(TIF)
Figure S2 Effect of AMPKa subunit deletion on the
expression of the second isoform in aortic lysates. While
deletion of the AMPKa2 subunit had no effect on the expression
of the AMPKa1 isoform, the deletion of AMPKa1 induced a
compensatory increase in AMPKa2 expression. Each lane
represents tissue from a different animal and identical results
were obtained in tissue from 4 additional animals.
(TIF)
Figure S3 Role of AMPKa2 in regulating the expression
and phosphorylation of p65. The phosphorylation of p65 NF-
kB was assessed in COS-7 cells expressing either constitutively
active (CA) or dominant negative (DN) AMPKa2 and stimulated
with solvent (Sol) or TNF-a (10 ng/mL). Data are expressed
relative to values obtained in control virus-infected cells. The bar
graph summarizes the results of 4 to 5 independent experiments;
*P,0.05 versus CA.
(TIF)
Figure S4 Effect of the AMPKa1 deletion on the IL1b (30 ng/
mL)-mediated phosphorylation of IKKa/b and IkB in mouse lung
endothelial cells. The bar graph summarizes the results of 4–5
independent experiments.
(TIF)
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